Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: URM002
MIFTS: 47

Uremia

Categories: Nephrological diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Uremia

About this section

MalaCards integrated aliases for Uremia:

Name: Uremia 11 75 53 43 14 16 71
Uremia of Renal Origin 11

Classifications:

MalaCards categories:
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

Disease Ontology 11 DOID:4676
MeSH 43 D014511
SNOMED-CT 68 44730006
ICD10 31 N19
UMLS 71 C0041948
Sources

Summaries for Uremia

About this section

MalaCards based summary: Uremia, also known as uremia of renal origin, is related to hyperparathyroidism and secondary hyperparathyroidism. An important gene associated with Uremia is EPO (Erythropoietin), and among its related pathways/superpathways are Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) and PI3K-Akt signaling pathway. The drugs Levoleucovorin and Folic acid have been mentioned in the context of this disorder. Affiliated tissues include kidney, pancreas and bone marrow, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia: 75 Uremia is the term for high levels of urea in the blood. Urea is one of the primary components of urine.... more...
Sources

Related Diseases for Uremia

About this section

Diseases related to Uremia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 730)
# Related Disease Score Top Affiliating Genes
1 hyperparathyroidism 31.2 VDR PTH FGF23 EPO CASR ALB
2 secondary hyperparathyroidism 31.0 VDR PTH FGF23 EPO CASR B2M
3 blood platelet disease 30.9 VWF EPO CRP ALB
4 hyperhomocysteinemia 30.9 VWF PON1 CRP ALB
5 glomerulonephritis 30.9 SPP1 NOS2 CRP B2M ALB
6 uremic neuropathy 30.8 PTH EPO B2M
7 aortic atherosclerosis 30.8 LPL INS CRP
8 renal osteodystrophy 30.8 VDR PTH FGF23 CASR
9 microvascular complications of diabetes 5 30.8 PON1 NOS2 INS ALB
10 pericarditis 30.8 RETN LEP CRP
11 amyloidosis 30.8 INS CRP B2M ALB
12 hypertriglyceridemia 1 30.8 LPL INS APOC3
13 hemorrhagic disease 30.7 VWF CRP ALB
14 chronic pyelonephritis 30.7 PTH EPO CRP B2M ALB
15 hyperphosphatemia 30.7 VDR SPP1 PTH FGF23 CRP CASR
16 osteomalacia 30.6 VDR PTH FGF23 CASR
17 bone disease 30.6 VDR SPP1 PTH FGF23 EPO CASR
18 osteitis fibrosa 30.6 PTH FGF23 CASR B2M
19 rickets 30.6 VDR SPP1 PTH FGF23 CASR ALB
20 autonomic nervous system disease 30.6 INS CRP ALB
21 urinary tract obstruction 30.6 CRP B2M ALB
22 peripheral nervous system disease 30.6 LEP INS EPO CRP B2M ALB
23 arteriosclerosis 30.5 SPP1 PON1 INS CRP
24 nutritional deficiency disease 30.5 RETN LEP GH1 EPO CRP ALB
25 interstitial nephritis 30.5 CRP B2M ALB
26 infective endocarditis 30.5 VWF CRP ALB
27 pulmonary edema 30.5 NOS2 EPO CRP
28 nephrolithiasis, calcium oxalate 30.5 VDR SPP1 CASR
29 autonomic neuropathy 30.5 INS EPO ALB
30 nephrotic syndrome 30.5 PON1 LPL INS EPO CRP B2M
31 acute kidney tubular necrosis 30.4 CRP B2M ALB
32 peptic ulcer disease 30.4 VWF INS CRP ALB
33 liver cirrhosis 30.4 RETN LEP INS ALB
34 active peptic ulcer disease 30.4 VWF CRP ALB
35 pulmonary tuberculosis 30.4 VDR CRP ALB
36 congestive heart failure 30.4 VWF INS EPO ALB
37 polycystic kidney disease 30.4 PTH INS FGF23 EPO CRP ALB
38 hypertensive encephalopathy 30.4 EPO CRP ALB
39 respiratory failure 30.3 VWF INS CRP ALB
40 parathyroid adenoma 30.3 VDR PTH CASR ALB
41 hydronephrosis 30.3 VWF CRP B2M ALB
42 proteasome-associated autoinflammatory syndrome 1 30.3 RETN NOS2 INS CRP ALB
43 urinary tract infection 30.3 INS CRP ALB
44 acute pancreatitis 30.3 RETN LPL INS CRP
45 renal hypertension 30.3 PTH INS EPO CRP ALB
46 hypercholesterolemia, familial, 1 30.3 LPL INS GHR CRP
47 glucose intolerance 30.2 RETN LPL LEP INS GH1 CRP
48 hypophosphatemia 30.2 VDR SPP1 PTH FGF23 ALB
49 substance abuse 30.2 INS CRP ALB
50 aortic valve insufficiency 30.2 VWF PON1 CRP ALB

Graphical network of the top 20 diseases related to Uremia:



Diseases related to Uremia
Sources

Symptoms & Phenotypes for Uremia

About this section

GenomeRNAi Phenotypes related to Uremia according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.21 AHSG ALB APOC3 B2M CASR CRP
2 no effect GR00402-S-2 10.21 AHSG ALB APOC3 B2M CASR CRP

MGI Mouse Phenotypes related to Uremia:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.49 AHSG ALB APOC3 B2M CASR CRP
2 growth/size/body region MP:0005378 10.32 AHSG APOC3 B2M CASR FGF23 GH1
3 muscle MP:0005369 10.31 AHSG ALB CASR EPO GHR INS
4 cardiovascular system MP:0005385 10.27 ALB B2M CRP EPO FGF23 GH1
5 liver/biliary system MP:0005370 10.26 ALB B2M EPO GH1 GHR INS
6 renal/urinary system MP:0005367 10.25 ALB CASR FGF23 GH1 GHR INS
7 cellular MP:0005384 10.25 ALB B2M CASR EPO GHR INS
8 immune system MP:0005387 10.22 ALB B2M CASR CRP EPO FGF23
9 endocrine/exocrine gland MP:0005379 10.2 ALB B2M CASR FGF23 GH1 GHR
10 adipose tissue MP:0005375 10.11 APOC3 GH1 GHR INS LEP LPL
11 digestive/alimentary MP:0005381 10.09 ALB B2M CASR FGF23 INS LEP
12 hematopoietic system MP:0005397 9.97 B2M CASR EPO FGF23 GH1 GHR
13 skeleton MP:0005390 9.96 AHSG CASR FGF23 GHR INS LEP
14 mortality/aging MP:0010768 9.83 ALB B2M CASR EPO FGF23 GH1
15 integument MP:0010771 9.28 B2M CASR FGF23 GHR INS LEP
Sources

Drugs & Therapeutics for Uremia

About this section

Drugs for Uremia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 46)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
2
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
3
Ascorbic acid Approved, Nutraceutical Phase 4 50-81-7 54676860 54670067 5785
4 Antioxidants Phase 4
5 Protective Agents Phase 4
6 Folate Phase 4
7 Vitamin B9 Phase 4
8 Vitamin B Complex Phase 4
9 Hematinics Phase 4
10 Vasodilator Agents Phase 4
11 Polymethyl Methacrylate Phase 4
12 Vitamins Phase 4
13 Trace Elements Phase 4
14 Micronutrients Phase 4
15 Dialysis Solutions Phase 3
16
Basiliximab Approved, Investigational Phase 1, Phase 2 179045-86-4
17
Bortezomib Approved, Investigational Phase 1, Phase 2 179324-69-7 387447 93860
18
Cysteine Approved, Nutraceutical Phase 2 52-90-4 594 5862
19 Immunosuppressive Agents Phase 1, Phase 2
20 Immunologic Factors Phase 1, Phase 2
21 Immunoglobulins Phase 1, Phase 2
22 Antibodies Phase 1, Phase 2
23 Pharmaceutical Solutions Phase 2
24
Gabapentin Approved, Investigational 60142-96-3 3446
25
Pancrelipase Approved, Investigational 53608-75-6 8519
26
Ritonavir Approved, Investigational Early Phase 1 155213-67-5 392622
27
Carbamide peroxide Approved 124-43-6
28
Gastric inhibitory polypeptide Investigational 100040-31-1
29
Indole Experimental 120-72-9 798
30 Anti-Anxiety Agents
31 Neurotransmitter Agents
32 Psychotropic Drugs
33 Excitatory Amino Acid Antagonists
34 Anticonvulsants
35 Analgesics
36 Anti-Infective Agents
37 Hormones
38 Glucagon-Like Peptide 1
39 Incretins
40 Pancreatin
41 Gastrointestinal Agents
42 Anti-Bacterial Agents Early Phase 1
43 HIV Protease Inhibitors Early Phase 1
44 Antibiotics, Antitubercular Early Phase 1
45
protease inhibitors Early Phase 1
46
D-Alanine Experimental, Nutraceutical 302-72-7, 338-69-2, 56-41-7 101757026 602 71080 5950

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 The Clinical Use of Probiotics in the Uremia Patients Under Chronic Peritoneal Dialysis Unknown status NCT01076426 Phase 4 Pro-biotics
2 Efficacy and Safety of a Very Low Protein Diet in Postponing Dialysis in Elderly: a Prospective Randomized Multicenter Controlled Study Completed NCT00388648 Phase 4 mixture of amino and keto acids
3 Randomized Clinical Trial of Folate Therapy/Placebo for Reduction of Homocysteine Serum Levels in Uremic Patients and Influence on Cardiovascular Mortality Completed NCT00317005 Phase 4 folate treatment
4 ACTIVE Dialysis - A Multicentre, Unblinded, Randomised, Controlled Trial to Assess Quality of Life, Clinical Outcomes and Cost Utility for Extended vs Standard Duration of Dialysis in Patients With End Stage Kidney Disease. Completed NCT00649298 Phase 4
5 Uremic Pruritus, Cytokines and Polymethylmethacrylate Artificial Kidney Completed NCT00442819 Phase 4
6 Effect of Oral Vitamin C on The Inflammatory Biomarkers in Hemodialysis Completed NCT01356433 Phase 4 oral vitamin C
7 The Effect and Safety of Combination Hemodialysis and Hemoperfusion on Severe Renal Osteopathy and Itching in Uremia Patients Completed NCT02747979 Phase 2, Phase 3
8 Effects of Convective Therapies in Dialysis Patients Completed NCT01583309 Phase 3
9 Effect of Autologous Stromal Vascular Fraction Derived Mesenchymal Stem Cell in Kidney Transplantation From Chinese Donation After Citizen Death (DCD): A Randomized Controlled Trial Unknown status NCT02492490 Phase 1, Phase 2 Basiliximab
10 A Prospective, Open-Label, Pilot Study of Clonal Deletion on Living-Relative Donor Kidney Transplantation Unknown status NCT01408797 Phase 1, Phase 2 MMF, Bortezomib
11 A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, CROSS-OVER STUDY TO EVALUATE THE RENAL AND BIOHUMORAL EFFECTS OF L-CYSTEINE COMPARED TO PLACEBO IN STABLE PERITONEAL DIALYSIS PATIENTS WITH RESIDUAL DIURESIS Completed NCT02050139 Phase 2
12 Clinical and Biochemical Effects of Multipass Hemodialysis Completed NCT01267760 Phase 2
13 Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma Withdrawn NCT00172367 Phase 2 Lycopene
14 Removal of Protein Bound Uremic Toxins in Chronic Hemodialysis Patients by Modified Plasma Separation and Adsorption Combined With Hemodialysis Unknown status NCT00375635
15 Probing the Dry Weight (DW) by Bioimpedance (BIA): Which is the Gold Standard Between Clinical DW and BIA DW? Unknown status NCT02606955
16 REST/Collaborative Study Initiative With the Aim of Providing More Objective Information on Volume Status and Guiding Physicians in the Quest for DW Unknown status NCT02446535
17 Long-term Follow Up of Viral Hepatitis in Uremic Patients in Taiwan Unknown status NCT01766895
18 Randomized Controlled Trial to Compare Therapeutic Effect of Digital Subtraction Angiography(DSA)，Ultrasound Guided Balloon Dilatation and Surgical Reconstruction in Arteria-venous Fistula(AVF) Stenosis in Maintenance Hemodialysis Patients Unknown status NCT02266238
19 Gabapentin - A Solution to Uremic Pruritus? A Prospective, Randomized, Placebo-controlled, Double-blind Study Unknown status NCT00577967 Gabapentin
20 Effect of Fructose and Glucose and TAS1R2 in Glucose, Triglycerides, Uremia, Oxidative Stress, Feelings Related to Food Intake of Individuals With Type 1 Diabetes Completed NCT01713023
21 In Vitro Evaluation of Antibacterial Activity of Urea Solution Against Ocular Bacterial Isolates Completed NCT04020406
22 Elimination and Biodegradation of the Incretin Hormones GLP-1 and GIP in Patients With End-stage Renal Disease Completed NCT01391884
23 Reduction Ratio and Clearance of Middle Molecules During a Single Hemodialysis Session With Medium Cut-Off (MCO) Filter Compared to Hemodiafiltration (HDF) With Standard High-flux Filter Completed NCT03437538
24 Detection and Identification of Preeclampsia Via Volatile Biomarkers Completed NCT01291342
25 Dysregulated Urea-synthesis at Terminal Uremia Recruiting NCT05076318
26 Clinical Analysis of Simultaneous Pancreas-kidney Transplantation for End-stage Renal Disease Associated With Diabetes Mellitus Recruiting NCT05497232
27 The Effect of Paxlovid in the Treatment of COVID-19 Patients With Uremia Not yet recruiting NCT05386433 Early Phase 1 Paxlovid;standard-of-care
28 Assessment of the Production of Uremic Toxins by the Gut Microbiota of Patients With Chronic Kidney Disease: in Vitro Test Not yet recruiting NCT04768309
29 Early vs Late CRRT, a Propensity Matched Multicenter Cohort Study Not yet recruiting NCT03629977
30 12 Weeks of Hemodialysis With Medium Cut-Off Filter Compared to Hemodiafiltration With Standard High-flux Filter. Withdrawn NCT03416192

Search NIH Clinical Center for Uremia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Activated Charcoal
Charcoal
CHARCOAL,ACTIVATED PWDR

Cochrane evidence based reviews: uremia

Sources

Genetic Tests for Uremia

About this section
Sources

Anatomical Context for Uremia

About this section

Organs/tissues related to Uremia:

MalaCards : Kidney, Pancreas, Bone Marrow, Endothelial, Skeletal Muscle, Bone, Smooth Muscle
Sources

Publications for Uremia

About this section

Articles related to Uremia:

(show top 50) (show all 9021)
# Title Authors PMID Year
1
The emerging pleiotrophic role of adipokines in the uremic phenotype. 53 62
19823084 2010
2
Serum-soluble Fas and serum levels of erythropoietin in chronic kidney disease. 53 62
20040346 2010
3
Antioxidant properties of some different molecular weight chitosans. 53 62
19559405 2009
4
Lipoprotein lipase disturbances induced by uremia and hemodialysis. 53 62
19708998 2009
5
Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. 53 62
19212416 2009
6
Antioxidant effects of a dietary supplement: reduction of indices of oxidative stress in normal subjects by water-soluble chitosan. 53 62
18996432 2009
7
Serum albumin fragmentation in end-stage renal disease patients--a pilot study. 53 62
19778290 2009
8
Antioxidant protection of human serum albumin by chitosan. 53 62
18514811 2008
9
Effect of simvastatin in apolipoprotein E deficient mice with surgically induced chronic renal failure. 53 62
18295249 2008
10
[Effects of metal-catalyzed oxidation on the formation of advanced oxidation protein products]. 53 62
18642767 2008
11
[Relationship between cardiovascular complication and inflammation, oxidative stress of patient with maintenance hemodialysis]. 53 62
18390217 2008
12
Response of the growth plate of uremic rats to human growth hormone and corticosteroids. 53 62
17665047 2007
13
Oxidative stress and delta-ALA-D activity in chronic renal failure patients. 53 62
17383846 2007
14
Alteration of serum semicarbazide-sensitive amine oxidase activity in chronic renal failure. 53 62
17431736 2007
15
Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis. 53 62
17259742 2007
16
Mechanisms of disease: Cytokine and adipokine signaling in uremic cachexia. 53 62
16941045 2006
17
Circulating osteoprotegerin affects bone metabolism in dialysis patients with mild secondary hyperparathyroidism. 53 62
16817791 2006
18
Circulating growth hormone binding protein levels and mononuclear cell growth hormone receptor expression in uremia. 53 62
16567271 2006
19
Drug-associated disease: hematologic dysfunction. 53 62
16678004 2006
20
Hyperleptinemia is not responsible for decreased paraoxonase activity in hemodialysis patients. 53 62
16534235 2006
21
Increased parathyroid hormone gene expression in secondary hyperparathyroidism of experimental uremia is reversed by calcimimetics: correlation with posttranslational modification of the trans acting factor AUF1. 53 62
16291838 2006
22
Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels. 53 62
16816924 2006
23
[Inflammatoin, oxidative stress and carbonyl stress in uremic patients]. 53 62
16468659 2006
24
Oxidation and carboxy methyl lysine-modification of albumin: possible involvement in the progression of oxidative stress in hemodialysis patients. 53 62
16671336 2005
25
Maxacalcitol therapy decreases circulating osteoprotegerin levels in dialysis patients with secondary hyperparathyroidism. 53 62
16047647 2005
26
Role of leptin and melanocortin signaling in uremia-associated cachexia. 53 62
15931394 2005
27
Quotidian nocturnal hemodialysis improves cytokine profile and enhances erythropoietin responsiveness. 53 62
15968953 2005
28
Growth hormone resistance in uremia, a role for impaired JAK/STAT signaling. 53 62
15692835 2005
29
The John F. Maher Recipient Lecture 2004: Rage in the peritoneum. 53 62
15770917 2005
30
Lymphocyte 5'-nucleotidase and aminopeptidase N activity in patients on maintenance hemodialysis treated with human recombinant erythropoietin and 1-alpha-D3. 53 62
15957544 2005
31
Serum paraoxonase activity in uremic predialysis and hemodialysis patients. 53 62
15593056 2004
32
Regulation of PTH1 receptor expression by uremic ultrafiltrate in UMR 106-01 osteoblast-like cells. 53 62
14871409 2004
33
Plasma cell membrane glycoprotein 1 (PC-1): a marker of insulin resistance in obesity, uremia and diabetes mellitus. 53 62
15209435 2004
34
Leptin, ghrelin, and proinflammatory cytokines: compounds with nutritional impact in chronic kidney disease? 53 62
14681862 2003
35
Involution of the parathyroid glands after renal transplantation. 53 62
12815332 2003
36
Paraoxonase activity and paraoxonase 1 gene polymorphism in patients with uremia. 53 62
12790379 2003
37
Contribution of quinolinic acid in the development of anemia in renal insufficiency. 53 62
12620922 2003
38
[Atherosclerosis and uremia: signifance of non-traditional risk factors]. 53 62
12778774 2003
39
[Renal bone disease and osteoprotegerin]. 53 62
15775096 2003
40
New markers of accelerated atherosclerosis in end-stage renal disease. 53 62
12649530 2003
41
Impaired protein binding of Chinese medicine DanShen in uremic sera and sera with hyperbilirubinemia: rapid assessment of total and free DanShen concentrations using the fluorescence polarization immunoassay for digoxin. 53 62
12938147 2003
42
Chronic liver and renal diseases differently affect structure of human serum albumin. 53 62
12485604 2002
43
The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. 53 62
12371953 2002
44
[The skeletal resistance to PTH and osteoprotegerin]. 53 62
15775364 2002
45
Novel erythropoiesis stimulating protein exerts an effect on platelet function in uremia equivalent to that exerted by recombinant human erythropoietin. 53 62
12010672 2002
46
Relationship of paraoxonase and serum lipids in Taiwan. 53 62
12149827 2002
47
[Some parameters of platelet activation in patients with uremia before and after hemodialysis (HD)]. 53 62
12731371 2002
48
Carnitine metabolism in uremia. 53 62
11576925 2001
49
Metabolic consequences of hyperhomocysteinemia in uremia. 53 62
11576929 2001
50
Osteoprotegerin levels before and after renal transplantation. 53 62
11576949 2001
Sources

Variations for Uremia

About this section
Sources

Expression for Uremia

About this section
Search GEO for disease gene expression data for Uremia.
Sources

Pathways for Uremia

About this section

Pathways related to Uremia according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 66
Show member pathways
 12.16 SPP1 FGF23 ALB AHSG
2
PI3K-Akt signaling pathway 74
Show member pathways
 12.03 VWF SPP1 NOS2 INS GHR GH1
3
Vitamin D receptor pathway 74
12.02 VDR SPP1 PTH FGF23
4
Endochondral ossification 74
Show member pathways
 11.72 GH1 GHR PTH SPP1
5
Adipogenesis 74
11.67 RETN LPL LEP INS GH1
6
HIF-1-alpha transcription factor network 61
11.47 NOS2 LEP EPO
7
Mesenchymal Stem Cells and Lineage-specific Markers 65
11.33 SPP1 PTH LPL LEP INS
8
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
11.26 VDR SPP1 PTH
9
FOXA2 and FOXA3 transcription factor networks 61
Show member pathways
 11.21 LPL INS ALB
10
Development_Hedgehog and PTH signaling pathways in bone and cartilage development 22
11.14 VDR SPP1 PTH
12
Vitamin D metabolism 74
10.51 VDR PTH
Sources

GO Terms for Uremia

About this section

Cellular components related to Uremia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.19 AHSG ALB APOC3 B2M CRP EPO
2 endoplasmic reticulum lumen GO:0005788 9.93 SPP1 INS FGF23 B2M ALB AHSG
3 extracellular space GO:0005615 9.85 AHSG ALB APOC3 B2M CRP EPO
4 growth hormone receptor complex GO:0070195 9.56 GHR GH1

Biological processes related to Uremia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.21 VDR PTH INS FGF23 CRP CASR
2 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 9.85 LEP GHR GH1
3 response to fibroblast growth factor GO:0071774 9.76 PTH CASR
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 LEP GHR GH1 EPO
5 prostaglandin secretion GO:0032310 9.71 NOS2 LEP
6 negative regulation of feeding behavior GO:2000252 9.62 INS RETN
7 positive regulation of vitamin D 24-hydroxylase activity GO:0010980 9.56 VDR FGF23
8 response to nutrient levels GO:0031667 9.43 PTH PON1 LEP GH1
9 acute-phase response GO:0006953 9.23 INS EPO CRP AHSG

Molecular functions related to Uremia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.4 RETN PTH LEP INS GH1 EPO
Sources

Sources for Uremia

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....